The estimated Net Worth of Brook H Byers is at least 22.8 百万$ dollars as of 21 July 2014. Brook Byers owns over 53,296 units of Veracyte Inc stock worth over 22,775,596$ and over the last 19 years Brook sold VCYT stock worth over 0$.
Brook has made over 1 trades of the Veracyte Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Brook bought 53,296 units of VCYT stock worth 532,960$ on 21 July 2014.
The largest trade Brook's ever made was buying 53,296 units of Veracyte Inc stock on 21 July 2014 worth over 532,960$. On average, Brook trades about 1,615 units every 0 days since 2005. As of 21 July 2014 Brook still owns at least 751,174 units of Veracyte Inc stock.
You can see the complete history of Brook Byers stock trades at the bottom of the page.
Brook's mailing address filed with the SEC is PACIFIC BIOSCIENCES OF CALIFORNIA, INC., 1380 WILLOW ROAD, MENLO PARK, CA, 94025.
Over the last 11 years, insiders at Veracyte Inc have traded over 201,983,044$ worth of Veracyte Inc stock and bought 75,122 units worth 1,149,322$ . The most active insiders traders include Group Holdings (Sbs) Adviso...、Nicole Vitullo、Jesse I Treu. On average, Veracyte Inc executives and independent directors trade stock every 20 days with the average trade being worth of 804,905$. The most recent stock trade was executed by John Leite on 4 September 2024, trading 5,479 units of VCYT stock currently worth 163,165$.
veracyte is a pioneering genomic diagnostics company. our tests are dramatically improving clinical outcomes for patients by resolving inconclusive results from traditional diagnostic methods. we ask the right questions to resolve ambiguity and bring assurance to light, rendering tens of thousands of costly and unnecessary surgeries truly unnecessary. we are giving patients a clearer path forward. through scientific rigor we employ the best tools, best science and best minds to create tests that enable a more accurate diagnosis without the need for risky, costly and often unnecessary surgery. veracyte consistently brings to bear evidence that is unprecedented in genomic tests, thereby changing today's clinical practice standards. we are making a difference in the lives of physicians and patients. we are doing something real. .
Veracyte Inc executives and other stock owners filed with the SEC include: